Frontiers in Science · Oct 22, 2026
The GPCR-ome as a central regulator of human healthspan
By Sakmar TP
• Age-related disruption of GPCR networks may connect inflammation, metabolic dysfunction, neurodegeneration, and other hallmarks of aging through shared signaling mechanisms.• Network-level GPCR targeting could move geroscience beyond single-receptor pharmacology toward coordinated, multisystem interventions tailored to aging biology.• AI, multiomics, and digital-twin approaches may enable more precise GPCR-based therapies, but their clinical value will depend on high-quality data, rigorous validation, and overcoming major translational and regulatory barriers.We are living in an era of remarkable global demographic shifts, with most people now expected to live into their seventies and many well beyond. However, this extension of lifespan has also highlighted a persistent gap in "healthspan"-the period of life spent free from chronic, debilitating conditions. Advanced age remains the primary risk factor for a broad spectrum of illnesses, including type 2 diabetes, cardiovascular disease, Alzheimer's disease and other dementias, and cancer. Because the care and treatment of people with these conditions and their comorbidities places an unsustainable strain on healthcare systems, the field of geroscience seeks to target the shared biological root causes of aging itself (1,2).Early therapeutic strategies in this space focused heavily on "senolytics"-compounds engineered to selectively eliminate senescent cells. However, translating senolytic agents from preclinical models to human patients has proven difficult. Because senescent cells share many internal survival pathways with healthy cells in vital tissues, first-generation senolytic approaches have raised concerns about significant systemic adverse effects, including blood disorders or impaired wound healing. These translational hurdles underline the ongoing need for therapeutic strategies with improved tissue selectivity and safety profiles.In their lead article, Boeringer et al. advocate for a systematic focus on the cell surface, specifically targeting G protein-coupled receptors (GPCRs) (1). The largest family of transmembrane proteins in the human genome, GPCRs modulate a wide range of hormonal, metabolic, neural, and immunological processes, many of which tend to undergo dysregulation with age (1,3). Because of their accessibility on the surfaces of virtually every cell, and their vital roles in endocrine, paracrine, and autocrine signaling, GPCRs are already the targets of more than one-third of current pharmacotherapeutics approved by the United States Food and Drug Administration.The authors build their case on a biological convergence across the five major, structurally distinct families: Class A (rhodopsin-like), Class B1 (secretin-like), Class B2 (adhesion), Class C (glutamate), and Class F (Frizzled/Smoothened) (1). Despite their notable structural differences, all five GPCR families show age-related changes in expression, trafficking, or signaling that can disrupt receptor function (1). Human physiological aging is associated with reductions in plasma membrane levels, increased internalization, and reduced heterotrimeric G protein coupling in Class A and Class B1 receptors, as well as defective mechanotransduction and altered dimer stability in Class B2 and Class C families (1). Class F receptors also display an age-related loss of homeostatic tone driven by increased levels of soluble functional antagonists. This convergence of age-related decay of signaling fidelity suggests that aging may act through shared downstream mechanisms, such as molecular chaperone dysfunction, lysosomal decay, and altered lipid raft composition, positioning the GPCR-ome as a deeply interconnected network (1). To understand how this network misfires over time, we must first map the physical and functional architecture that links these families together. Our laboratory has focused on decoding this underlying structural complexity, using multiplexed mapping strategies to systematically chart the functional interactome of GPCRs alongside their critical receptor activity-modifying accessory networks (4). This system-wide interconnectivity underpins Boeringer et al.'s argument that the GPCR-ome behaves as a deeply integrated molecular switchboard (1), providing a rational basis for moving beyond traditional single-receptor pharmacology toward a broader, network-level strategy for rebalancing cellular signaling in aging.One of the most practical applications of this cell-surface framework is the modulation of the cellular secretome, particularly the senescence-associated secretory phenotype (SASP).Senescent cells drive localized tissue damage by developing a SASP and secreting a complex mixture of proinflammatory cytokines, growth factors, and proteases that promote chronic inflammation and drive age-related pathologies across multiple organs (2).The lead article maps how chronic perturbations in specific Class A receptors are linked to systemic and progressive "inflammaging" (1). Specifically, age-associated increases in chemokine receptors, including C-X-C chemokine receptors 2 and 4 (CXCR2/4) and C-C chemokine receptors 2 and 5 (CCR2/5), directly fuel persistent leukocyte activation and chronic inflammation. In this context, the authors highlight the potential of senomorphics to counteract some of these changes using small-molecule therapeutics to modulate or suppress specific hyperactive surface receptors, which in turn may modify or block the production of toxic SASP factors without killing the cell outright (1). Identifying and targeting GPCR pairings that regulate specific proinflammatory interleukins could interrupt the localized inflammatory cascade, thereby protecting surrounding tissues and organs.An important tension in geroscience is the dual role of cellular senescence. Senescence serves as a vital biological defense against oncogenesis, forcing severely damaged or mutated cells into permanent cell-cycle arrest to act as an emergency tumor brake. Consequently, broad or uncritical ablation of senescent cells carries the risk of removing beneficial tumor-suppressive functions of senescence and potentially increasing a patient's vulnerability to cancer. Conversely, leaving senescent cells completely unchecked allows chronic SASP secretions to steadily degrade the surrounding extracellular matrix, creating a microenvironment for tumors to grow, escape immune detection, and metastasize.Our work exploring the intersection of these signaling pathways has shown that specific receptor complexes can modulate both proliferation and senescence entry, depending on how they are engaged (5). Boeringer et al. propose GPCR-targeted interventions as a potential therapeutic strategy because these receptors communicate through highly specific, multilayered downstream pathways that are amenable to fine-tuned pharmacological regulation (1). For example, "biased" GPCR ligands can, in principle, be engineered to alter selected receptor conformations to engage beneficial signaling pathways while minimizing off-target effects. In this context, biased ligands could induce a cell to shut down its cancer-promoting inflammatory secretions while leaving its internal, tumor-suppressing cell-cycle arrest mechanisms intact. Furthermore, distinct surface expression profiles and unique structural patterns that arise on aged cells could act as precise molecular docking stations (6,7) to allow longevity researchers to guide antibody-drug conjugates or smart nanoparticles directly to target cells.Boeringer et al. successfully contextualize the broader systemic impact of GPCR networks by examining metabolic health and neurodegeneration as examples (1). In metabolic regulation, receptors responsive to incretin hormones, such as glucagon-like peptide 1 receptor (GLP-1R), undergo age-related declines in responsiveness that impair insulin sensitivity, disrupt glucose handling, and contribute to type 2 diabetes. Conversely, the Class B1 glucagon receptor (GCGR) exhibits pathological hypersensitivity in the liver with age, accelerating hepatic steatosis and driving the mitochondrial overload and insulin resistance seen in metabolic syndrome. Restoring nutrient homeostasis and targeting downstream cell-surface pathways show immense promise in rescuing β-cell function, maintaining cellular proliferation, and protecting vasculature from hyperglycemia-induced senescence (8)(9)(10). Medicines with multi-incretin agonist activity that optimize these cell-surface networks show promise in restoring proper nutrient sensing and activating downstream protective pathways.For neurodegenerative conditions such as Alzheimer's and Parkinson's diseases, Class A, Class B2, and Class C receptors are known to modulate pathological mechanisms, including neuroinflammation, excitotoxicity, and synaptic plasticity. The authors highlight a striking metric: large-scale genetic analyses have identified 22 specific GPCRs with direct links to Alzheimer's traits, yet fewer than 15% of these genetically identified targets are actively being explored in current clinical trials (3). This statistic serves as a clarion call that current pharmaceutical drug development pipelines may not be ideally suited to developing drugs for heterogeneous or multisystem disorders. Rather than aggressively responding to robust genetic population data, the current drug-discovery infrastructure remains anchored to legacy targets, leaving a vast, highly accessible reservoir of brain-specific receptors largely unexploited.While the conceptual framework linking the GPCR-ome to the hallmarks of aging is compelling, it is crucial to distinguish genuine data-driven insights from predictions generated by artificial intelligence (AI). Boeringer et al. outline a forward-looking technological roadmap that integrates AI for state-specific structural modeling, quantum computing for atomic-precision docking simulations, and multiomics data integration to build patient-specific "digital twins."While it is certainly likely that next-generation medicine will integrate many of these tools to improve healthcare outcomes, stubborn translational bottlenecks are hampering current progress.Simulating an entire human multireceptor signaling network via quantum machine learning that might influence healthcare practice remains an interesting but currently hypothetical exercise. As the authors acknowledge, these advanced deep learning models operate as "black boxes" that are limited by the quality, scope, and curation of human-derived training data, which remain sparse, heavily fragmented, and poorly standardized across the academic literature. Furthermore, designing multireceptor interventions is notoriously difficult due to the inherent promiscuity and pleiotropic nature of GPCR signaling systems. Translating a theoretically perfect AI-generated drug network into a safe, nontoxic, and stable polypharmacological regimen might require years of empirical validation, iterative preclinical testing, and resolution of massive regulatory hurdles regarding composite healthspan endpoints (1).In summary, Boeringer et al. provide a highly useful synthesis of how cell-surface signaling interfaces with the complex, multisystemic processes of aging. By framing age-related health decline as part of a larger, systemic drift in GPCR network balance at the cellular level-where hyperactivation of pro-aging receptors coexists with hypoactivation of pro-longevity receptorsthe authors offer a cohesive perspective that connects disparate fields of aging research.While a universal therapeutic solution remains aspirational, evaluating the GPCR-ome as an integrated molecular switchboard provides geroscience with a structured, data-driven approach to systems pharmacology (1). The lead article's computational pathways provide a useful roadmap for long-term future investigation. Ultimately, continued interdisciplinary investment in mapping the cell-surface landscape of the GPCR-ome will be essential to determine whether these network-level strategies can be translated to clinical applications with the aim of extending human healthspan.